CRYOFOCUS MEDTECH (SHANGHAI) CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.18 HKD | +1.54% |
|
+32.33% | -29.97% |
| 03-27 | Cryofocus Medtech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 01-15 | Cryofocus Medtech Gets Marketing Approval in China for Cryoadhesion System | MT |
| Sales 2023 | 40.95M 5.66M 44.18M 450M | Sales 2024 * | 171M 23.69M 185M 1.89B | Capitalization | 2.92B 403M 3.15B 32.09B |
|---|---|---|---|---|---|
| Net income 2023 | -97M -13.4M -105M -1.07B | Net income 2024 * | -67M -9.25M -72.29M -737M | EV / Sales 2023 | 99.9 x |
| Net cash position 2023 * | - 0 0 0 | Net cash position 2024 * | - 0 0 0 | EV / Sales 2024 * | 17 x |
| P/E ratio 2023 |
-41.7
x | P/E ratio 2024 * |
-42.8
x | Employees | 392 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 14.17% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.54% | ||
| 1 week | +32.33% | ||
| Current month | +7.50% | ||
| 1 month | +39.18% | ||
| 3 months | +23.18% | ||
| 6 months | -30.26% | ||
| Current year | -29.97% |
1 week
10.34
13.18
1 month
9.6413.18
Current year
6.0018.82
1 year
6.0019.50
3 years
6.0019.50
5 years
6.0019.50
10 years
6.0019.50
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Zhu
CEO | Chief Executive Officer | 50 | 30/04/19 |
Jia Wei Li
CHM | Chairman | 34 | 31/05/21 |
Wei Liu
DFI | Director of Finance/CFO | 34 | 30/09/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hsien-Tse Liang
BRD | Director/Board Member | 69 | 01/12/21 |
Shi Wen Lv
BRD | Director/Board Member | 55 | 30/06/14 |
Jun Zhu
CEO | Chief Executive Officer | 50 | 30/04/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 13.18 | +1.54% | 7 600 |
| 02/05/24 | 12.98 | +5.87% | 9,400 |
| 30/04/24 | 12.26 | +8.11% | 10,600 |
| 29/04/24 | 11.34 | +13.51% | 9,800 |
| 26/04/24 | 9.99 | +0.30% | 10,600 |
Delayed Quote Hong Kong S.E., May 03, 2024 at 09:09 am
More quotes
Cryofocus Medtech Shanghai Co Ltd is a China-based medical device company, focusing on the research, development and commercialization of cryotherapy devices. The Company has built a comprehensive product portfolio comprising two core products, approximately 15 other product candidates in various development stages as well as approximately six additional commercialized medical consumables. The two core products comprise the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Company's products mainly target two therapeutic areas: natural orifice transluminal endoscopic surgery, to treat urinary, respiratory, and digestive diseases (such as bladder cancer, COPD, asthma, airway stenosis, gastric cancer, esophageal cancer and others), and vascular interventional therapy to treat cardiovascular diseases (such as atrial fibrillation, hypertension and others).
Sector
Pharmaceuticals
Calendar
30/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
12.21
CNY
Average target price
25.57
CNY
Spread / Average Target
+109.43%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.97% | 397M | |
| +26.77% | 681B | |
| +21.85% | 556B | |
| -4.96% | 361B | |
| +17.12% | 325B | |
| +5.24% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -4.24% | 157B |
- Stock Market
- Equities
- 6922 Stock
